Cll Cells
Cll Cells - Related Videos
03:40
Density Gradient Centrifugation: A Method to Isolate CLL Cells from Peripheral Blood
0 Views •
2023
This video describes the technique of isolating chronic lymphocytic leukemia (CLL) cells from peripheral blood. With this protocol, we will isolate CLL cells from human patient blood sample for subsequent efficient generation of nuclear and cytoplasmic fractions.
03:06
Negative Immunomagnetic Selection: A Method to Purify B-cells from Peripheral Blood Mononuclear Cells
0 Views •
2023
The video explains a way to purify B-cells by immunomagnetic targeting and separation from peripheral blood mononuclear cells suspension. The method involve labeling unwanted cell types with specific antibodies or ligands (linked to magnetic particles) targeting specific cell surface proteins, to be depleted from the heterogenous cell suspension by magnetic separation.
11:29
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
0 Views •
Cited by 5 •
2016
The protocol described here represents an easy and reproducible method that employs reverse phase high-performance liquid chromatography (RP-HPLC) to measure purine metabolism on chronic lymphocytic leukemia (CLL) cells cultured under different conditions.
05:01
Extracellular Purine Metabolism: An HPLC-based Assay to Measure Adenosine Generation and Metabolism in Leukemic Cells
0 Views •
2023
This video explains a quantitative reverse phase high-performance liquid chromatography (RP-HPLC) method to measure metabolism of adenosine and associated purines generated by consumption of AMP in extracellular environment of leukemic cancer cells. The protocol describes a sensitive, specific, reliable and reproducible RP-HPLC assay developed and validated for the quantification of extracellular purine nucleotides and nucleosides produced by purified chronic lymphocytic leukemia (CLL) cells...
10:18
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
0 Views •
Cited by 3 •
2014
Here we describe a protocol that couples two proteomic techniques, namely 2-dimensional Electrophoresis (2DE) and Mass Spectrometry (MS), to identify differentially expressed/post-translational modified proteins among two or more groups of primary samples. This approach, together with functional experiments, allows the identification and characterization of prognostic markers/therapeutic targets.
FAQs
Disrupted apoptotic control allows CLL cells to survive longer than expected, contributing to their accumulation in blood, bone marrow, and lymphoid tissues. Chemically, this persistence can be investigated by examining changes in protein activity, gene expression, and cellular metabolism. These molecular alterations help explain why some cells remain viable and why their responses to treatment may differ.
B-cell receptor signaling influences intracellular activity and can modify how CLL cells respond to pathway inhibition. Analyzing this signaling provides a way to connect receptor-driven molecular changes with treatment sensitivity. In chemistry-focused research, such analysis supports the evaluation of compounds designed to interfere with specific signaling processes rather than affecting cellular behavior without a defined molecular target.
Differences in protein activity, gene expression, and cellular metabolism can indicate how CLL cells may respond to a treatment. Biomarker analysis and molecular profiling are used to examine these features and relate them to sensitivity or persistence. This information can help researchers interpret why a compound produces different effects across cellular samples without relying on a single measurement.
A chemistry-based investigation may combine molecular profiling, biomarker analysis, drug-binding tests, and pathway-inhibition studies. Molecular profiling examines cellular changes, while biomarkers provide measurable indicators associated with disease behavior or treatment response. Binding and inhibition experiments then connect a compound’s interaction or pathway effect with changes observed in the cells, supporting more focused evaluation of therapeutic candidates.
These studies can connect a compound’s binding behavior or pathway-inhibitory activity with cellular responses. Researchers use that connection to assess whether a targeted compound affects the molecular processes associated with CLL cell persistence or treatment sensitivity. The resulting information supports comparison of candidate compounds and helps identify approaches that act more selectively on relevant cellular pathways.
Molecular profiles and biomarkers can contribute to disease classification by linking measurable cellular features with leukemia biology. Testing drug binding and pathway inhibition adds information about how those features relate to therapeutic response. Together, these approaches help evaluate targeted compounds, identify patterns of treatment sensitivity, and guide development of more selective strategies for managing leukemia.